STAT

STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more

STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and moreWorldPing

Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug.Read the latest pharma headlines in today's…

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT

Related news